Skip to content

Study on lipidomics analysis of meibomian gland dysfunction

Study on lipidomics analysis of meibomian gland dysfunction

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109408
Enrollment
Unknown
Registered
2025-09-17
Start date
2024-12-30
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian gland dysfunction

Interventions

Meibomian gland dysfunction with hyperlipidemia group :None

Sponsors

Yangpu District Central Hospital, Shanghai (Yangpu Hospital,Tongji University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meibomian gland dysfunction group:1. Age range: 18-80 years old 2. Participants volunteer to participate and sign an informed consent form 3. Cooperate with relevant medical history collection and eye examination 4. Meets the diagnostic criteria for meibomian gland dysfunction. Meibomian gland dysfunction with hyperlipidemia group: 1. Age range: 18-80 years old 2. Participants volunteer to participate and sign an informed consent form 3. Cooperate with relevant medical history collection and eye examination 4. Meets the diagnostic criteria for meibomian gland dysfunction. 5.According to the 2007 Chinese Guidelines for the Prevention and Treatment of Adult Dyslipidemia, blood lipid diagnosis is based on triglycerides (TG) = 2.26mmol/L, serum total cholesterol (TC) = 6.22mmol/L, low-density lipoprotein cholesterol (LDL-C) = 4.14mmol/L, and high-density lipoprotein cholesterol (HDL-C)<1.04mmol/L, If one of the above indicators exceeds the standard, the patient is diagnosed with hyperlipidemia and also diagnosed with MGD.

Exclusion criteria

Exclusion criteria: Meibomian gland dysfunction group : 1. Age80 years old; 2. History of severe ocular surface diseases or ocular inflammation, ocular surface anatomical abnormalities; 3. In the past month or currently using topical or systemic antibiotics for the eyes; 4. Currently using methods other than artificial tears to treat MGD; 5. History of eye trauma or surgery in the past year; 6. Patients with severe systemic diseases (such as Sjogren's syndrome, connective tissue disease, etc.); 7. Patients who suspect or have a history of alcohol, drug abuse, or mental illness; 8. Pregnant or preparing pregnant women, breastfeeding women; 9. Medications that can cause dryness symptoms (such as anticholinergic drugs) used within the past year Meibomian gland dysfunction with hyperlipidemia group :The exclusion criteria are the same as those for meibomian gland dysfunction group

Design outcomes

Primary

MeasureTime frame
Lipidomics analysis;Blood indicators;ocularsurfacediseaseindex,OSDI;Eyelid margin score;

Secondary

MeasureTime frame
Thickness of tear film lipid layer;Meibomian gland deficiency rate;Corneal fluorescein staining score;tear film break-up time,TBUT;Schirmer?Test;Meibomian gland opening score;

Countries

China

Contacts

Public ContactChenYihui

Yangpu District Central Hospital, Shanghai (Yangpu Hospital,Tongji University)

cyh80h@163.com+86 193 0122 1798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026